Edition:
United Kingdom

Aradigm Corp (ARDM.OQ)

ARDM.OQ on NASDAQ Stock Exchange Capital Market

1.56USD
22 Jun 2018
Change (% chg)

$-0.10 (-6.02%)
Prev Close
$1.66
Open
$1.60
Day's High
$1.62
Day's Low
$1.54
Volume
4,844
Avg. Vol
14,686
52-wk High
$7.26
52-wk Low
$1.04

Chart for

About

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery... (more)

Overall

Beta: 1.63
Market Cap(Mil.): $55.61
Shares Outstanding(Mil.): 15.11
Dividend: --
Yield (%): --

Financials

  ARDM.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -1.27 -- --
ROI: -96.52 2.00 14.38
ROE: -394.66 3.49 16.08

BRIEF-Aradigm Announces EMA Has Completed Its Validation Of The MAA Submission

* ARADIGM ANNOUNCES THE EMA HAS COMPLETED ITS VALIDATION OF THE MAA SUBMISSION

05 Apr 2018

BRIEF-Aradigm Reports Q4 Loss Per Share Of $0.28

* ARADIGM ANNOUNCES FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS

23 Mar 2018

BRIEF-Aradigm Submits Marketing Authorisation Application To EMA For EU Marketing Approval Of Linhaliq

* ARADIGM SUBMITS MARKETING AUTHORISATION APPLICATION (MAA) TO EMA FOR EU MARKETING APPROVAL OF LINHALIQ IN NON-CYSTIC FIBROSIS BRONCHIECTASIS Source text for Eikon: Further company coverage:

09 Mar 2018

BRIEF-FDA Declines To Approve Aradigm's Drug Linhaliq

* ARADIGM RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR LINHALIQ NDA

29 Jan 2018

BUZZ-Aradigm Corp: Ladenburg Thalmann cuts rating to 'neutral'

** Drug developer's shares plunge 42.7 pct to $1.96 premarket - top pct loser among all U.S.-listed stocks

12 Jan 2018

BRIEF-Aradigm - FDA Advisory Committee Did Not Recommend Approval For Linhaliq

* ARADIGM REPORTS RESULTS OF FDA ADVISORY COMMITTEE MEETING ON LINHALIQ‍​

11 Jan 2018

Earnings vs. Estimates